Nonetheless, the authors suggested the standard use of GnRH antagonist in PCOS patients and poor responders due to less OHSS but comparable OPR in GnRH antagonist protocol group in these two populations. This evidence concerns the gene GNRH1 and polycystic ovary syndrome.